28th week of 2017 patent applcation highlights part 7 |
Patent application number | Title | Published |
20170196760 | OBTAINING, WITH A SLEEP-APNEA DEVICE, INFORMATION RELATED TO SLEEP-APNEA EVENTS AND SLEEP-APNEA TREATMENT, AND CORRELATING SLEEP APNEA EVENTS AND SLEEP-APNEA TREATMENT WITH SUBJECT LIFESTYLE AND WELLBEING - An embodiment of a system for treating sleep apnea includes a collar, pump, motor, sensor, memory, and controller, which is configured to store, in the memory, information related to sleep-apnea events or sleep-apnea treatment, experienced by the subject. For example, the controller can obtain, and store in the memory, information related to sleep-apnea events, and the controller, or another computing system, can correlate this information with the subject's lifestyle choices, and can recommend lifestyle changes to improve the subject's sleep apnea. Furthermore, the controller can obtain and store, in the memory, information related to usage and settings of the sleep-apnea system, and the controller, or another computing system, can correlate this information with the subject's wellbeing, and can recommend changes in the usage or the settings of the sleep-apnea system that can improve the subject's wellbeing. | 2017-07-13 |
20170196761 | TREATING SLEEP APNEA WITH NEGATIVE PRESSURE - An embodiment of a system for treating sleep apnea includes a collar, a pump, a motor, a sensor, and a controller. The collar is configured to maintain an airway of a subject open while the subject is sleeping by applying, to a throat of the subject, a negative pressure having a magnitude, and the pump is configured to generate the negative pressure. The motor is configured to drive the pump, and the sensor is configured to generate a sense signal that is related to a degree to which the airway is open. And the controller is configured to vary the magnitude of the negative pressure in response to the sense signal. For example, one or more of the pump, motor, sensor, and controller can be secured to the collar such that the system is self-contained, i.e., the entire sleep-apnea system can be worn by the subject. | 2017-07-13 |
20170196762 | Pulmonary Expansion Therapy (PXT) Devices - A pulmonary expansion therapy (PXT) device may be a handheld device that covers specific lung fields and may generate negative pressure fields locally. The device also may provide vibratory/percussion therapy for airway clearance. The PXT may generate a localized negative pressure field non-invasively to the exterior of the chest wall, thereby increasing the functional residual capacity in underlying lung fields. As a result, increased ventilation and perfusion to the targeted internal lung field may be achieved by creating a decrease in the external barometric pressure relative to the more positive intrinsic airway pressures. The PXT device also may improve lung compliance by enabling a medical professional to grab and elevate the chest wall to compensate for the dysfunction of the respiratory musculature responsible for lifting the chest wall. In some embodiments, once a targeted functional residual capacity (FRC) has been established, vibration or percussion may be applied. | 2017-07-13 |
20170196763 | INTERMITTENT AND SEQUENTIAL COMPRESSION DEVICE AND METHOD - An intermittent and sequential compression device accommodates an angular placement and application of the device as used within a limb support. The support can incorporate a variety of supports and braces of the type that can be used with human limbs, and the joints of such limbs, in particular. Disposed within the support is a plurality of sequentially-disposed and intermittently inflatable and deflatable air chambers. Each air chamber has an air inlet port and an air outlet port, which can be the same structure or different structure. Each chamber port is to the first end of an air-passage tube. The second end of the air-passage tube is connected a pneumatic pump, the pneumatic pump being connected to an electric power supply and to a controller. The controller operates in accordance with a pre-programmed scheme to alternate the inflation and deflation of the air chambers. | 2017-07-13 |
20170196764 | Leg Muscle Massage Apparatus - A leg massage apparatus is provided which enables the user to easily and comfortable engage the various muscles of the leg, providing the leg muscles with a therapeutic massage which helps to loosen and relieve sore or damages muscles. The apparatus may also be used to assist in the removal of cellulite from areas of the leg. The apparatus is basically comprised of a name structure means, a user engagement means, a coupling means, and an optional resistance means. The frame structure means has at least two main support members coupled together in such a manner that the leg of the user may be placed within, with the main support members surrounding a significant portion of the leg. The main support members are adjustably coupled together by the coupling means such that they may alternatively move away and towards one another, as the various leg muscles of the user are being engaged by the user engagement means. The optional resistance means may be used to provide motion resistance. | 2017-07-13 |
20170196765 | Cold foot pain reliever - A system for adding pressure and extracting heat from the bottom of a user's foot to aid in pain relief. A spherical container is provided with an aqueous polymer mixture which may be cooled or heated to allow heat to be transferred through the spherical container to/from the bottom of a user's foot. The spherical container is provided with a tube passing therethrough to allow a user to provide a strap through the spherical container. The strap is provided with handles to allow the user to direct the pressure of the spherical container to the bottom of the user's foot and to extract or apply heat as desired | 2017-07-13 |
20170196766 | METHOD FOR IMPOROVING KIDNEY FUNCTION WITH EXTRACORPOREAL SHOCKWAVES - The present invention relates to a method for treating the kidney with extracorporeal shockwaves in a noninvasive manner and in particular, to such a method for the treatment of the nephrons about the glomerulus. | 2017-07-13 |
20170196767 | EMERGENCY MEDICAL GLOVES - A pair of gloves for performing cardiopulmonary resuscitation (CPR) is disclosed. The left hand glove comprises a sensor detector in form of heart shape, or the like. The right hand glove is provided with green and red light sensors in the shape of arrows. In use, the left hand glove is placed over a patient's heart for detecting heartbeats wherein the right hand glove's green light sensor indicates when it's time to blow into the patient's lungs and red light sensor indicates when it's time to push down and pump the patient's chest. | 2017-07-13 |
20170196768 | METHOD AND APPARATUS FOR ENHANCEMENT OF CHEST COMPRESSIONS DURING CPR - An apparatus for assisting a rescuer in performing chest compressions during CPR on a victim, the apparatus comprising a pad or other structure configured to be applied to the chest near or at the location at which the rescuer applies force to produce the chest compressions, at least one sensor connected to the pad, the sensor being configured to sense movement of the chest or force applied to the chest, processing circuitry for processing the output of the sensor to determine whether the rescuer is substantially releasing the chest following chest compressions, and at least one prompting element connected to the processing circuitry for providing the rescuer with information as to whether the chest is being substantially released following chest compressions. | 2017-07-13 |
20170196769 | INTEGRATED RESUSCITATION - A resuscitation system for use by a rescuer for resuscitating a patient, comprising at least two high-voltage defibrillation electrodes, a first electrical unit comprising circuitry for providing resuscitation prompts to the rescuer, a second electrical unit separate from the first unit and comprising circuitry for providing defibrillation pulses to the electrodes, and circuitry for providing at least one electrical connection between the first and second units. In another aspect, at least two electrical therapy electrodes adapted to be worn by the patient for extended periods of time, circuitry for monitoring the ECG of the patient, an activity sensor adapted to be worn by the patient and capable of providing an output from which the patient's current activity can be estimated, and at least one processor configured for estimating the patient's current activity by analyzing the output of the activity sensor, analyzing the ECG of the patient, and determining whether electrical therapy should be delivered to the electrodes. | 2017-07-13 |
20170196770 | Container Holder Assembly - Container holder assembly for use in a medicament delivery device, comprising a tubular body elongated in an axial direction, said tubular body having a proximal end and an opposite distal end, and a retaining member releasably arranged to said tubular body for securing an elongated container placed inside the tubular body, wherein said retaining member comprises a resilient structure capable of exerting an axial force on said container in said tubular body for holding the container in a fixed position inside the tubular body and thereby avoiding displacement or breakage of the container and wherein a distal end of said container protrudes from a distal end of said tubular body. | 2017-07-13 |
20170196771 | Medical Fluid Transfer and Injection Apparatus and Method - Drug delivery system, injection device, transfer apparatus, vial holder and method of administering and transferring are disclosed which provide for passive warming of chilled injectable transferred through the transfer apparatus and into the injection device. The injection device may include a skin-facing surface including a skin boundary displacement extension or structure around a needle injection site to create a high pressure zone in the tissue. Radio frequency tracking and monitoring features for tracking patient compliance also may be provided. | 2017-07-13 |
20170196772 | FLUID TRANSFER APPARATUS WITH FILTERED AIR INPUT - In certain embodiments, a vial adaptor for removing liquid contents from a vial comprises a piercing member and a bag. The bag can be contained within the piercing member such that the bag is introduced to the vial when the vial adaptor is coupled with the vial. In some embodiments, the bag expands within the vial as liquid is removed from the vial via the adaptor, thereby regulating pressure within the vial. In other embodiments, a vial comprises a bag for regulating pressure within the vial as liquid is removed therefrom. In some embodiments, a vial adaptor is coupled with the vial in order to remove the liquid. In some embodiments, as the liquid is removed from the vial via the adaptor, the bag expands within the vial, and in other embodiments, the bag contracts within the vial. | 2017-07-13 |
20170196773 | FLUID TRANSFER APPARATUS WITH PRESSURE REGULATION - In certain embodiments, a vial adaptor for removing liquid contents from a vial comprises a piercing member and a bag. The bag can be contained within the piercing member such that the bag is introduced to the vial when the vial adaptor is coupled with the vial. In some embodiments, the bag expands within the vial as liquid is removed from the vial via the adaptor, thereby regulating pressure within the vial. In other embodiments, a vial comprises a bag for regulating pressure within the vial as liquid is removed therefrom. In some embodiments, a vial adaptor is coupled with the vial in order to remove the liquid. In some embodiments, as the liquid is removed from the vial via the adaptor, the bag expands within the vial, and in other embodiments, the bag contracts within the vial. | 2017-07-13 |
20170196774 | MEDICATION DISPENSER BRACELET WITH VIBRATING ALARM AND BLUETOOTH COMMUNICATION - The present invention is a bracelet that contains a cartridge holding a plurality of interior storage compartments that are each designed to hold one or more pills. A sliding door is used to withdraw the pills from any one compartment at a time. The bracelet comprises electronic components that enable it to activate a vibrating alarm at a prearranged time to remind the user to take her pills, and to track when the door has been opened to withdraw the pills, and to communicate the alarm and tracking information to an external electronic device, such as a mobile phone, via Bluetooth wireless communication. | 2017-07-13 |
20170196775 | NOVEL DELIVERY DEVICES AND METHODS - Generally provided herein is a device for the delivery of liquids. In particular, a delivery device that attaches to a nipple and increases the accuracy and comfort when delivering medication to an infant/child. | 2017-07-13 |
20170196776 | Absorbent Neck Ring for a Baby Bottle - The invention is directed to an absorbent neck ring for a baby bottle which is disc shaped with an aperture at the center. The ring is fitted to the bottle, preferably with elasticized cotton or other elastic fabric such that the aperture passes over the bottle opening and is secured below the screw fixtures when the cap is attached to the bottle. The ring ensures that any leaks from the bottle or the baby's mouth will be absorbed, rather than dripping on clothing or elsewhere. The ring may be laundered and re-used, or it may be used in a single use capacity. The ring may be provided in various colors and decorative configurations, such as an image of a teddy bear's face or a baseball. | 2017-07-13 |
20170196777 | Kit and Method for Detecting Porous Dental Hydroxyapatite - The present invention relates to a kit and a probe for detecting porous dental hydroxyapatite that includes a protein capable of binding porous dental hydroxyapatite or a detector thereof. The invention also relates to a method for detecting a condition involving porous dental hydroxyapatite that includes detecting in or on a tooth or a sample of the tooth of a subject a protein bound to porous dental hydroxyapatite. The invention also relates to methods for detecting a hypomineralisation developmental dental defect or detecting intact and/or broken MIH enamel, and to a kit and method for removing a protein bound to porous dental hydroxyapatite. | 2017-07-13 |
20170196778 | DENTAL ADHESIVE - The present invention provides a dental adhesive exhibiting excellent initial bond strength and bond durability to both enamel and dentin. The present invention relates to a dental adhesive containing: an asymmetric acrylamide-methacrylic acid ester compound (a); an acid group-containing (meth)acrylic polymerizable monomer (b); and a water-soluble polymerizable monomer (c). The asymmetric acrylamide-methacrylic acid ester compound (a) is represented by the following general formula (1): | 2017-07-13 |
20170196779 | COSMETIC COMPOSITION CONTAINING AMPHIPHILIC ANISOTROPIC POWDER AND METHOD FOR PREPARING SAME - Disclosed are a cosmetic composition containing an amphiphilic anisotropic powder and a method for preparing the same. The cosmetic composition contains an amphiphilic anisotropic powder which maximizes chemical interface activity and physical interface activity by controlling amphiphilic property, which is the characteristic of an existing surfactant, and geometric property, which is the characteristic of powder macroparticles, thereby forming an emulsion having excellent and stabilized emulsifying capacity. | 2017-07-13 |
20170196780 | FOAMING CLEANSER - The invention relates to a foaming cleanser cosmetic composition containing, in a physiologically acceptable medium: —a surfactant system comprising (i) at least one N—(C6-C30)acyl-amino based surfactant and (ii) at least one amphoteric surfactant chosen from betaines or (C8-C20)alkyl betaines, (C8-C20)alkylamido(C1-C6)alkylbetaines and mixtures thereof; and—at least one non associative crosslinked copolymer or acrylic acid and/or methacrylic acid, and optionally of (C1-C4)alkyl esters thereof, wherein said N—(C6-C30)acyl-amino based surfactant being present in the surfactant system in a major weight amount, and the surfactant system being present in the composition in an amount of less than 15% by weight relative to the total weight of the composition. The invention also relates to a process for cleansing keratin materials, which consists in applying the said composition to the said keratin materials, in working it into a foam and then in rinsing off the said composition, as well as the cosmetic use of the composition as defined above, for removing makeup and/or cleansing the skin, the hair and/or mucous membranes, or for skincare. | 2017-07-13 |
20170196781 | ANHYDROUS SOLID COMPOSITION BASED ON PARTICLES ENCAPSULATING A BENEFICIAL AGENT - The present invention relates to a solid anhydrous composition comprising:
| 2017-07-13 |
20170196782 | TREATMENT OF SKIN, INCLUDING AGING SKIN, TO IMPROVE APPEARANCE - The present invention generally relates to compositions and methods for transdermal delivery, treatment of skin, and improving the appearance of skin. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2017-07-13 |
20170196783 | PHARYNGEAL OR BUCCAL CAVITY RINSE AND PROCESS OF USE THEREOF - A storage stable package is provided that includes a polymeric bottle having a volume filled with an aqueous saline composition acidified with an acid to a pH of 2 to 9 and having a hypertonic saline concentration relative to saliva and blood, or an aqueous hydrogen peroxide composition acidified with an acid to a pH of 2.7 to 5.3 and having a hydrogen peroxide concentration 0.5 to 3 total weight percent, either to achieve a storage stability at 20 degrees Celsius of the composition of at least 10 weeks. The aqueous composition is independent of a synthetic antimicrobial. A cap is provided that is complementary a package opening for selectively sealing the aqueous saline composition within the volume. A process for treating an infection of a pharyngeal or buccal cavity is provided that includes rinsing with one of the aqueous saline composition. The aqueous saline composition is then expectorated. | 2017-07-13 |
20170196784 | ORAL CARE COMPOSITIONS - The present invention relates generally to oral care compositions, and more specifically to oral care compositions suitable for cleaning the oral cavity. Methods of use are also disclosed. | 2017-07-13 |
20170196785 | SOLID ANHYDROUS COMPOSITION FOR KERATIN FIBERS - Present invention is on an anhydrous solid conditioning and styling, composition for keratin fibres, especially human hair. The object of the present invention is a solid anhydrous composition for keratin fibres, especially for human hair, comprising at least one polyol liquid at 20° C. at a concentration 50% or more by weight and at least one fatty acid soap at a concentration of 5% or more by weight, all values calculated to total composition, wherein the composition is free of volatile organic solvents, especially C | 2017-07-13 |
20170196786 | Extended Release Fragrance Compositions - Compositions are provided that provide fragrance over an extended period of time. The compositions comprise a fragrance and one or more other ingredients. | 2017-07-13 |
20170196787 | DISPOSABLE WIPES COMPRISING OF WARMING LUBRICANTS, VITAMIN E OIL, AND ESSENTIAL OILS - Disposable wipes comprising of warming lubricants, glycerol and capsaicin, vitamin E oil, essential oils, Lavender and Lemon, and propyl paraben. The fragrance free disposable wipes comprises of 85% purified water, 0.4.% glycerol, 0.1% capsaicin, 0.9% vitamin E oil, and 0.1% propyl paraben. The disposable wipes with fragrance comprises of 80% purified water, 0.4.% glycerol, 0.1% capsaicin, 0.9% vitamin E oil, 0.5% of either the essential oils, Lavender or Lemon, and 0.1% propyl paraben. The warming effect is achieved by having one or more additives in the lubricant which are either always active or activated by your body. | 2017-07-13 |
20170196788 | SUNSCREEN/INSECT REPELLANT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - The present invention is directed to combination sunscreen and insect repellant compositions. The combination sunscreen and insect repellant compositions contain (i) diethyl toluamide (or N,N-Diethyl-3-methylbenzamide or DEET), (ii) one or more sunscreen components, with each sunscreen component being capable of absorbing ultraviolet light rays, and (iii) a polymeric binder system. The combination sunscreen and insect repellant compositions may contain additional composition components such as butyloctyl salicylate, a crosslinked polyacrylate polymer, and deionized water. The present invention is also directed to methods of making and using combination sunscreen and insect repellant compositions. | 2017-07-13 |
20170196789 | REDUCTION OF ORAL AND EPIDERMAL MALODOR IN HUMANS AND ANIMALS - Some methods for preventing or reducing oral and epidermal malodor by the use of formulations for reducing bacteria are introduced, including applying various formulations for reducing bacteria to the oral cavity, the nasal cavity, and/or the epidermis of a user or an animal. The formulations for removing and/or reducing bacteria are applied to the oral cavity via delivery devices, including, but not limited to, a toothbrush, aerosol can, roll-on bottle, bar, and bottle, and the oral formulations for reducing bacteria can take various forms, including, but not limited to, a liquid, pellet, powder or granule, cream, spray or stick. Formulations for reducing bacteria can be applied to the epidermis of a user for removal and/or reduction of bacteria by use of a delivery device including, but not limited to, a toothbrush, aerosol can, roll-on bottle, bar, and bottle, and the epidermal formulations for reducing bacteria can take various forms, including, but not limited to a spray, roll-on, gel, solid, liquid, cream, or stick. | 2017-07-13 |
20170196790 | HAIR DYE COMPOSITION - A hair dye composition comprising the following components (A), (B) and (C) and having pH (25° C.) of 7.5 or more and 12 or less:
| 2017-07-13 |
20170196791 | HAIR-DYE COMPOSITION - A hair dye composition comprising the following components (A) and (B), in which the mass ratio of the component (B) to the component (A), (B)/(A), in a whole composition is 1 or more and 100 or less and the pH (25° C.) during application is 7.5 to 12:
| 2017-07-13 |
20170196792 | HAIR-DYE COMPOSITION - A hair dye composition comprising the following components (A) and (B), in which the mass ratio of the component (B) to the component (A), (B)/(A), in a whole composition is 1 or more and 100 or less and the pH (25° C.) during application is 7.5 to 12:
| 2017-07-13 |
20170196793 | HAIR GROWTH COMPOSITION AND METHOD - The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active and a C | 2017-07-13 |
20170196794 | Oral Composition - The present invention relates to a dentifrice composition which removes a fine stain and a stain adhering to the surface of teeth sufficiently, enhances the whitening effect on teeth and the gloss-imparting effect on teeth, also increases the amount of fluorine adsorption to teeth, and decreases the feeling of astringency. The oral composition of the present invention comprises the following component (A): phytic acid or an alkali metal salt thereof in an amount of 0.04% by mass or more and 1% by mass or less in terms of phytic acid; and component (B): monofluorophosphoric acid or an alkali metal salt thereof in an amount of 500 ppm or more and 1500 ppm or less in terms of fluorine atoms, wherein a mass ratio of the component (A) to the component (B), ((A)/(B)), is 0.1 or more and 1.4 or less, and a fluoride ion-supplying compound (F) selected from the group consisting of sodium fluoride, potassium fluoride and ammonium fluoride, a polyvalent metal cation, and a polyphosphoric acid or a salt thereof are comprised in a limited amount, and the pH thereof is from 5.5 to 6.5. | 2017-07-13 |
20170196795 | Method of Treating a Skin Condition and Compositions Therefor - Cosmetic methods and compositions for improving the appearance and barrier function of skin. The methods and compositions utilize a combination of niacinamide and a suitable saccharide at low pH to decrease trans-epidermal water loss in skin, reduce the size of hyperpigmented spots, and improve the appearance of skin better than their high pH counterparts. | 2017-07-13 |
20170196796 | Natural Silicone Replacements for Silicone Fluids In Personal Care Formulations - Described herein is a silicone replacement for use in a personal care formulation comprising a mixture of at least one polymeric ester and at least one non-polymeric ester. The polymeric ester is an esterification reaction product of (i) at least one first dicarboxylic acid, (ii) at least one first monofunctional alcohol or monofunctional carboxylic acid and (iii) glycerin or derivatives thereof. The non-polymeric ester is an esterification reaction product of (i) at least one second dicarboxylic acid and (ii) at least one second monofunctional alcohol, wherein the replacement is substantially free of silicone. | 2017-07-13 |
20170196797 | COMPOSITION CONTAINING GLYCINE GRACILIS OIL - Disclosed is a composition containing | 2017-07-13 |
20170196798 | BODY SCRUB COMPOSITIONS AND METHODS FOR FORMING BODY SCRUB COMPOSITIONS - Body scrub compositions and methods for forming body scrub compositions are provided herein. In one embodiment, a body scrub composition includes safflower oil, argan oil, and manila oil. Further, the body composition includes silica as a suspension agent. | 2017-07-13 |
20170196799 | SKINCARE STIMULANT HAVING A PLATELET DRY POWDER - A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, wherein the effective dose refers to the presence of at least 1000 platelets in every milligram of skincare stimulant. | 2017-07-13 |
20170196800 | MUCOADHESIVE DEVICES FOR DELIVERY OF ACTIVE AGENTS - Described herein are systems and methods for transmucosal delivery of active agents. In some embodiments, a system may comprise one or more mucoadhesive devices configured for release of an active agent. | 2017-07-13 |
20170196801 | APPLICATION OF TOPICAL PRODUCT USING A SONIC DEVICE - A method is provided comprising steps for (a) dispensing a topical product having a set of ingredients, wherein the set of ingredients provides pain relief to an affected area of a user; and (b) delivering the topical product via a sonic device to the affected area of a user, wherein the affected area includes joint inflammation, wherein the sonic device comprises an elongated body having an massager head receiving area designed to receive a massager head, the combination of the sonic device and the attached massager head producing a vibrating massager promoting optimal absorption of the set of ingredients designed to stimulate and increase blood flow to the joint inflammation providing a reduction of pain for the user, wherein the sonic device and topical product are packaged together in a single packaging unit. | 2017-07-13 |
20170196802 | Long Acting Injectable Formulations - The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C | 2017-07-13 |
20170196803 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY - A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. | 2017-07-13 |
20170196804 | METHOD FOR THE TREATMENT OF EAR INFECTIONS - A method for treating ear infections in animals includes forming a liquid composition having an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, an anhydrous organic acid, liquid dehydrated alcohol, and propylene glycol. The treatment method includes applying several drops of such composition inside the ear of the animal at least twice per day to the affected area of the animal's ear until the ear infection has been cured. The antifungal agent may include ketoconazole. The antibiotic agent may include ofloxacin. The steroidal anti-inflammatory agent may include triamcinolone diacetate. The anhydrous organic acid may include citric acid. | 2017-07-13 |
20170196805 | Ophthalmic Composition For The Treatment Of Ocular Infection - An ophthalmic composition for administration to an eye of a patient for the treatment of an ocular infection. The ophthalmic composition contains an ε-polylysine (εPL) in an amount effective to treat or control or prevent the ocular infection. | 2017-07-13 |
20170196806 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS - Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous MCP-1, a MCP-1 antagonist, a substance capable of suppressing endogenous TNF-alpha, a TNF-alpha antagonist, a substance capable of suppressing endogenous IL-1 beta, an IL-1 beta antagonist, a substance capable of inducing endogenous bFGF, exogenous bFGF, a bFGF mimetic, and combinations thereof, to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment. | 2017-07-13 |
20170196807 | PROPOFOL-CONTAINING OIL-IN-WATER EMULSION COMPOSITION AND METHOD FOR PRODUCING SAME - Provided are a propofol-containing oil-in-water emulsion composition having high stability even in a case in which the emulsion composition is charged into a plastic container; and a method for producing the same. Provided is a propofol-containing oil-in-water emulsion composition including at least one selected from the group consisting of trishydroxymethylaminomethane, phosphoric acid, and triethanolamine; propofol; an oily component; an emulsifier; and water, in which a dissolved oxygen concentration is 5 mg/L or less and an average emulsion particle size is 180 nm or less. | 2017-07-13 |
20170196808 | METHOD OF OBTAINING A PHARMACOLOGICALLY ACTIVE LIPOSOMAL QUERCETIN-CONTAINING PRODUCT - The invention discloses a new method of obtaining a pharmacologically active product that is a liposomal composition of phospholipid phosphatidylcholine and physiologically active substance—quercetin (3,3′, 4′, 5, 7-pentaoxyflavone). The substance of the invention to provide a method of optimized parameters sequential processes of dissolution, emulsification, dispersion and lyophilization that results in liposomal quercetin product with proven independent methods liposomal organisation, high stability and pharmacological activity. The high quality of the target product produced by the method claimed ensures the benefits of level and dynamics of integral pharmacological effect in non-clinical study, as compared with liposomal quercetin product produced by the the prototype method. The polytropic pharmacotherapeutic activity of the target product with demonstrated high level of harmlessness by different routes of administration, was to prove in the model of subtotal myocardial ischemia and reperfusion isolated heart performance in Guinea pigs by Langendorff method (the antiarrhythmic effect, normalisation of functional and hemodynamic characteristics of the myocardium), and also at the traumatic keratitis (reparative and anti-inflammatory effect). The invention is intended for use in pharmacy and medicine as a way to obtain a competitive product pharmacotherapy ophthalmologic and cardiologic diseases, adequate to different routes of administration. | 2017-07-13 |
20170196809 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST - Encapsulated nucleic acid nanoparticles of uniformly small particle size are produced by intersecting one or more nucleic acid streams with one or more lipid streams. The encapsulated nucleic acid nanoparticles include a nucleic acid encapsulated within a lipid nanoparticle host. Uniformly small particle sizes are obtained by intersecting an aqueous nucleic acid stream and a stream of lipids in organic solvent at high linear velocities and with total organic solvent concentrations less than 33%. | 2017-07-13 |
20170196810 | Processes For Producing Protein Microparticles - Processes and apparatuses for producing biologically-active, protein-rich microparticles under ambient conditions are disclosed. A protein solution is atomized and collected in a dehydration solvent that is being mixed. The resulting protein microparticles retain high specific activity without the need for large amounts of stabilizing excipients. | 2017-07-13 |
20170196811 | CORE-SHELL PARTICLE FORMULATION FOR DELIVERING MULTIPLE THERAPEUTIC AGENTS - A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases. | 2017-07-13 |
20170196812 | BIOCHARS FOR USE WITH ANIMALS - Biochars and methods for treating biochars are provided that are useful in various applications, including, but not limited to, applications related to the raising, care, maintenance, disease prevention, disease treatment and odor control of animals. | 2017-07-13 |
20170196813 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 2017-07-13 |
20170196814 | SUSTAINED RELEASE BEADS AND SUSPENSIONS INCLUDING THE SAME FOR SUSTAINED DELIVERY OF ACTIVE INGREDIENTS - Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product. | 2017-07-13 |
20170196815 | MEDICAMENT-CONTAINING HOLLOW PARTICLE - The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer. | 2017-07-13 |
20170196816 | LASER-PRINTABLE TABLET, AND METHOD FOR MANUFACTURING THE SAME - A laser-printable tablet has: a tablet containing an optically unstable drug, a first cover layer that covers the tablet and contains a first color change-inducing oxide, and a second cover layer that covers the first cover layer and contains a second color change-inducing oxide, the concentration in which the second color change-inducing oxide is contained in the second cover layer being different from the concentration in which the first color change-inducing oxide is contained in the first cover layer. | 2017-07-13 |
20170196817 | Methods for Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release. | 2017-07-13 |
20170196818 | HYDROGEL COMPOSITIONS COMPRISING ENCAPSULATED CELLS AND METHODS OF USE THEREOF - The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compositions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject. | 2017-07-13 |
20170196819 | PHARMACOTHERAPEUTIC BIOADHESIVE COMPOSITION - Embodiments of the claimed invention are directed to a biodegradable mucosal bioadhesive composition that delivers a therapeutic agent specifically to the target site, without loss to saliva or absorption by non-targeted areas. In certain embodiments, the outer layer of the composition also protects the covered area from physical contact. | 2017-07-13 |
20170196820 | Anti-cancer activity of (E)-1-(3',4'-Dimethoxyphenyl)butadiene - The present invention provides a method of using (E)-1-(3′, 4′-dimethoxyphenyl) butadiene to induce anti-tumorigenic effects in pancreatic carcinoma, ovarian carcinoma and prostate carcinoma. The invention also provides a method of using (E)-1-(3′, 4′-dimethoxyphenyl) butadiene to prevent cancer metastasis. | 2017-07-13 |
20170196821 | Method of Inhibiting Mucin Secretion - A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin. | 2017-07-13 |
20170196822 | Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety - The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety. | 2017-07-13 |
20170196823 | Urea Cream Formulations - A topical cream may include urea and one or more additional active agents such as fluticasone, itraconazole, and mupirocin. The topical cream may be formulated as a lotion, gel, ointment, foam, cream, or emulsion | 2017-07-13 |
20170196824 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR JOINT STABILITY - The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to decrease joint instability, increase joint stability, decrease joint stiffness, improve joint function, improve joint health, improve balanced movement and improve skeletal joint stability during muscle movement. HMB is administered to increase muscle strength and/or muscle mass in a side of the body contralateral to joint inflammation, joint damage, and/or joint injury. | 2017-07-13 |
20170196825 | PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME - The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and methods of using same to treat a variety of conditions and disorders. | 2017-07-13 |
20170196826 | Oligomeric forms of 3-hydroxybutyrate - The present invention relates to medicaments based on oligomeric forms of 3-hydroxybutyrate, particularly 3-hydroxybutyrate methyl ester dimer (1) and trimer (2), especially for use in treating, preventing and/or inhibiting development of a disorder or condition related to oxidative stress. The present invention relates also to the use of these molecules as antioxidants, and to a method for increasing proliferation and viability of plant cells in the aid of molecules 1 and 2. | 2017-07-13 |
20170196827 | Ketone Bodies To Protect Tissues From Damage By Ionizing Radiation - Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage. | 2017-07-13 |
20170196828 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof. | 2017-07-13 |
20170196829 | METHODS OF TREATING AGE RELATED DISORDERS - The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor. | 2017-07-13 |
20170196830 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION - The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers. | 2017-07-13 |
20170196831 | NANOPARTICLE COMPLEXES OF PACLITAXEL, ANTI-HER2 ANTIBODY, AND ALBUMIN - Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses HER2. | 2017-07-13 |
20170196832 | NANOPARTICLE COMPLEXES OF PACLITAXEL, ANTI-CD52 ANTIBODIES, AND ALBUMIN - Described are nanoparticle complexes comprising paclitaxel, albumin and anti-CD52 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses CD52. | 2017-07-13 |
20170196833 | NANOPARTICLE COMPLEXES OF PACLITAXEL, BEVACIZUMAB, AND ALBUMIN - Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses VEGF. | 2017-07-13 |
20170196834 | PREPARATION AND APPLICATION OF FLAVONOL AS BRAIN-TARGETING SYNERGIST - The present invention discloses a preparation and application of flavonol as a brain-targeting synergist. After long-term repeated studies, the inventors have found that some flavonol compounds, particularly kaempferide, rutin, troxerutin, myricetin, hesperidin, and hydroxy derivatives thereof, in particular their glycoside, ester, ether derivatives, can promote the drug molecules that have therapeutic or healthcare effect, such as ginsenoside, stilbene glucoside, resveratrol, levodopa, edaravone, vinpocetine, nicergoline, citicoline, oxiracetam, to enter brain tissues, to dramatically enhance drugs concentrations in the brain tissues and effective enhance the efficacy of drugs without increasing the plasma concentration. | 2017-07-13 |
20170196835 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT - The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific protein, EGFR inhibitor, HER2 inhibitor, and immune stimulating therapy and a method of using the combination for treating or preventing cancer. | 2017-07-13 |
20170196836 | Lung Cancer Adjuvant Therapy - The present invention includes compositions and methods for the treatment of cancer comprising an antineoplastic drug and an inhibitor of chromosome maintenance region 1 (CRM1) protein expression or activity, wherein the inhibitor of CRM1 enhances the anti-neoplastic effect of the antineoplastic drug. | 2017-07-13 |
20170196837 | FORMULATIONS WITH REDUCED OXIDATION - The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation. | 2017-07-13 |
20170196838 | Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection - The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection. | 2017-07-13 |
20170196839 | NEURODEGENERATIVE DISEASES AND METHODS OF MODELING - The invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1. | 2017-07-13 |
20170196840 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO ANDROGEN RECEPTOR THERAPY - Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides. Also described herein are methods of using the modified androgen receptor polypeptides as screening agents for the identification and design of third-generation androgen receptor modulators. Also described herein are third-generation androgen receptor modulators that inhibit the activity of the modified androgen receptor polypeptides. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions, including cancers, such as castration resistant prostate cancers, that are mediated or dependent upon androgen receptors. | 2017-07-13 |
20170196841 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE- -2-CARBONYL)AMINO]PENTANOIC ACID - In one aspect, the invention relates to a compound of the structure: | 2017-07-13 |
20170196842 | METHODS OF TREATMENT USING A 1,2,4-OXADIAZOLE BENZOIC ACID - Provided herein are methods of treating, preventing, ameliorating or managing mucopolysaccharidosis (nmMPS) disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nmMPS. In particular, provided herein are methods of treating, preventing, ameliorating or managing a MPS. | 2017-07-13 |
20170196843 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE - The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation. | 2017-07-13 |
20170196844 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS - The present invention relates to compounds of Formula (I): | 2017-07-13 |
20170196845 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective amount of at least one compound of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof. The pharmaceutical composition includes at least one compound of the General Formula (I) or the General Formula (II) for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease. | 2017-07-13 |
20170196846 | METHODS FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER WITH METHYLPHENIDATE - The invention relates to methods of treating attention deficit hyperactivity disorder in patients in need thereof, and methods for selecting therapeutic dosage amounts to achieve the desired efficacy more quickly. More specifically, the methods of the present invention provide for methylphenidate treatment regimens wherein the efficacious dosage amounts are selected based upon the body weight of the patient to be treated. | 2017-07-13 |
20170196847 | FORMULATIONS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)M- ETHYL)-2,2-DIFLUOROACETAMIDE - Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein. | 2017-07-13 |
20170196848 | Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives - The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment. | 2017-07-13 |
20170196849 | HCV NS-3 SERINE PROTEASE INHIBITORS - Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. | 2017-07-13 |
20170196850 | Heterocyclic GSK-3 Allosteric Modulators - The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes. | 2017-07-13 |
20170196852 | Composition and Method for Treating Chagas Disease - The presently disclosed subject matter provides a pharmaceutical composition and a method of treating Chagas disease. The pharmaceutical composition includes a dose of Itraconazole and a dose of Amiodarone and may be in the form of a liquid oral suspension. The liquid oral suspension may be produced through the use of pharmaceutically acceptable beads. In addition, the Itraconazole may be micronized to a small particle size before being formed into a composition with Amiodarone. The method for treating Chagas disease is effected by administering an effective amount of this pharmaceutical composition to a subject in need thereof, and the present composition is safer and more effective than previous compositions and with fewer undesirable side effects. | 2017-07-13 |
20170196853 | USE OF AN INHIBITOR OF KINASE ACTIVITY, PARTICULARLY MASITINIB, FOR TREATMENT OF PROSTATE CANCER - A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-Kit, PDGFR, LYN, FYN, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient. | 2017-07-13 |
20170196854 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS - This invention is directed to compounds and salts that are generally useful as agents to treat an infection with | 2017-07-13 |
20170196855 | Long Acting Injectable Formulations - The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 μm to about 25 μm in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C. | 2017-07-13 |
20170196856 | Pharmaceutical Compositions Comprising Sorbitan Esters - The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs. | 2017-07-13 |
20170196857 | METHODS AND COMPOSITIONS FOR KILLING SENESCENT CELLS AND FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS - Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. | 2017-07-13 |
20170196858 | METHODS AND COMPOSITIONS FOR KILLING SENESCENT CELLS AND FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS - Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. | 2017-07-13 |
20170196859 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT - [Problem] Provided is a pharmaceutical composition for treating cancer in which one or more kinases of BTK, JAK3, and ITK is involved. | 2017-07-13 |
20170196860 | Novel Uses - This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use. | 2017-07-13 |